Navigating the 2026 Regulatory Shift: Is Your AI Ready for FDA/EMA Scrutiny?
The March 2026 Regulatory Intelligence Digest by Boyds highlights a transformative era in drug development. As the FDA and EMA accelerate global collaboration through initiatives like Project Orbis, the bar for Data Integrity and Audit Trails has never been higher.
For Biotech founders and Regulatory Affairs teams currently in the IND-enabling phase, the challenge is clear: How do you maintain the speed of innovation while meeting the exponentially growing demands of CMC documentation and clinical compliance?
At Angelonia AI, we believe the answer lies in "Transparent Automation." The 2026 guidelines signal the end of "Black Box" AI. To succeed, AI agents must provide:
Full Traceability: Every data point in your Module 3 must be auditable.Human-in-the-loop (HITL): Empowering experts, not replacing them.Cross-border Alignment: Seamlessly adapting to harmonized global standards.
We aren't just building a medical writing tool; we are engineering the regulatory infrastructure for the next generation of life-saving therapies.Are you leveraging AI to accelerate your IND filing, or is manual paperwork still holding you back?
hashtag#Biotech hashtag#RegulatoryIntelligence hashtag#DrugDiscovery hashtag#AI hashtag#FDA hashtag#EMA hashtag#IND hashtag#CMC
